Pharmadule Morimatsu returns to ISPE Annual Meeting
Press Release | Pharmadule Morimatsu AB
SEPTEMBER 21, 2016
Nacka, Stockholm: – Swedish-based designer and engineer for the pharma and biotech industries, Pharmadule Morimatsu AB (Pharmadule) has returned to America’s leading pharma engineering event, ISPE 2016.
Pharmadule is an exhibitor at the ISPE Annual Meeting in Atlanta. The Pharmadule Morimatsu team at Table 617 is showcasing the company’s world-renowned expertise in constructing modular facilities for the pharma and biotech industries, along with expertise in QbD process design and engineering, facility design and engineering, fabrication and project management.
The Pharmadule team will also have information on the company’s turnkey design and construction services, modular off-site production solutions, commissioning and qualification expertise, GMP consultancy and extended after-sales services.
“ISPE in Atlanta provides a great platform from which to share our thinking in advanced design/build for the pharmaceutical and biopharma industries,” commented Pharmadule Morimatsu Director Business Development Leo Fallgren.
“The International Society for Pharmaceutical Engineering is one of the key organizations for our industry and it is always a pleasure to attend their annual meeting,” Fallgren added.
The company will also be using the exhibition’s networking opportunities to identify forthcoming project leads and partners, reaching out to executive and senior managers in engineering & facilities, process technology, process science, operations/facility development and biopharmaceutical operations.
Come along and meet Shanghai Morimatsu Pharmaceuticals (SMP) at Table #716 with details on process equipment and Extreme Modularization solutions for your projects.
About Pharmadule Morimatsu
Pharmadule Morimatsu designs and builds turnkey production facilities for the pharma and biopharma Industries. Pharmadule services extend from conceptual design to IQOQ qualifications completion, offering a one-stop-shop suite of services that include: Front-End Design & Pre-Engineering, Detailed Design, Fabrication, Quality Assurance (QA) and Validation Management.
The company was founded in 1986, since when it has successfully delivered more than 60 production facilities worldwide for clients including Eli Lilly, Merck, Baxter, GlaxoSmithKline, Genentech, Pharmacia and AstraZeneca, forging The Pharmadule Way as a way of offering unique value and reassurance to customers, with off-site construction and modular design concepts to provide very high predictability of on time, on budget delivery and consistent high quality, regardless of final location.
Since 2011, Pharmadule has been part of the Morimatsu Group of Japan, forming Pharmadule Morimatsu AB, headquartered in Stockholm, Sweden. The company also has a strong presence in Asia with engineering and manufacturing facilities in Shanghai, providing an enhanced service for clients in new markets.
About ISPE 2016
ISPE, the International Society for Pharmaceutical Engineering, is one of the world’s largest not-for-profit associations, committed to the advancement of the efficiency of its members through exchange of ideas and practical experience. Founded in 1980, the Society now numbers more than 20,000 members in 90 countries.
The ISPE 2016 Annual Meeting is a four-day event opening September 18 at the Atlanta Marriott Marquis Hotel.
This year’s conference has attracted more than 1,500 delegates from some 30 countries, along with 185 exhibitors.
The 2016 meeting introduces a new track, “Women in Pharma”, with addresses from female industry leaders. The ‘Regulatory Town Hall’ meeting, introduced in 2015 makes a reappearance.
The event is organized by iSpeak in partnership with Pharmaceutical Engineering magazine, with more information at:http://www.ispe.org/annualmeeting
Leo Fallgren, Director Business Development, Pharmadule AB
Tel: +46 (0)8 587 42 000
Click on Pharmadule Morimatsu returns to ISPE Annual Meeting for more information.
Click on Pharmadule to contact the company directly.